AspenBio Pharma, Inc. 4
4 · AspenBio Pharma, Inc. · Filed Jan 22, 2008
Insider Transaction Report
Form 4
Donnelly Richard G
DirectorPresident & CEO
Transactions
- Purchase
Common Stock
2008-01-18$6.75/sh+4,000$27,000→ 324,681 total
Holdings
- 100,000
Stock Options
Exercise: $2.96From: 2007-01-24Exp: 2017-01-24→ Common Stock (100,000 underlying) - 75,000
Stock Options
Exercise: $1.40From: 2007-01-01Exp: 2016-07-14→ Common Stock (75,000 underlying) - 5,000(indirect: By IRA)
Common Stock
- 500,000
Stock Options
Exercise: $0.60From: 2005-02-01Exp: 2015-02-01→ Common Stock (500,000 underlying)
Footnotes (3)
- [F1]Options vest over three years, at the rate of 33.3% at the end of year one, 66.7% at the end of year two, and 100% at the end of year three.
- [F2]Options were granted pursuant to Board approval on July 14, 2006 and were exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F3]Options and shares of common stock were granted pursuant to Board approval on January 24, 2007. The aggregate number of stock options granted was 100,000. One-third (33,333) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).